Mereo Makes Senior Appointments
This article was originally published in Scrip
Recently-formed biopharmaceutical company Mereo BioPharma Group Ltd. has appointed new members to its senior management and board. Paul Blackburn has been appointed non-executive board director and chair of the audit and risk committee; he joins Mereo from GlaxoSmithKline (GSK), where he was finance controller for almost 40 years. Anthony Hall has been appointed head of orphan diseases and previously was group medical director in the neuromuscular disease area at BioMarin. Jacqueline Parkin has been appointed Mereo's head of respiratory and endocrinology and joins the company from GSK where she held various senior clinical development roles for the past 13 years. Fiona Bor has been appointed head of intellectual property for Mereo and was previously vice president and global head of IP at Mylan Pharmaceuticals. Mereo has also appointed Ian Hodgson head of clinical operations; prior to this he was associate director, clinical operations and EMEA regional oncology lead at Takeda Oncology Company. In addition to these appointments, Stewart Jones has been appointed head of CMC, Craig Manchip head of QA and Julian Lord financial controller.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.